Kinesin-13 and STING Inhibition for Metastatic Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as surgery, radiotherapy, and chemotherapy, are inadequate in addressing metastasis due to lack of selectivity and toxicity issues, while immunotherapy has limitations in cytokine use and vaccine tolerance, and chromosomal instability contributes to cancer cell metastasis.
Innovation Solution
Methods and compositions that modulate kinesin-13 expression, inhibit specific signaling pathways like STING and NF-κB, and administer compounds to reduce chromosomal instability, metastasis, and cancer drug resistance, including the use of kinesin-13 proteins like Kif2b, MCAK/Kif2c, and ABCC4/ABCG2, and inhibit STING, cGAS, and NF-κB transcription factors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If surgery is used to remove tumor cells, then localized tumor mass is reduced, but extensively metastasized tumor cells cannot be completely removed
Solution Approach 1:
The patent extracts and targets specific molecular mechanisms (cytosolic DNA sensing pathways, chromosomal instability markers) that drive metastasis, separating the treatment of metastatic potential from bulk tumor removal. By inhibiting cGAS-STING pathway and targeting kinesin-13 proteins, the treatment specifically addresses metastatic cells that surgery cannot reach.
2Productivity
If radiotherapy and chemotherapy are used to kill cancer cells, then cancer cell proliferation is inhibited, but these treatments lack selectivity and cause toxicity to rapidly proliferating normal cells
Solution Approach 1:
The patent applies local quality by targeting specific molecular pathways (cGAS-STING, NF-κB) that are dysregulated in metastatic cancer cells but not in normal cells. Treatments such as cGAS inhibitors and kinesin-13 modulators selectively affect cancer cells with chromosomal instability while sparing normal proliferating cells, achieving local specificity at the molecular level.
Solution Approach 2:
The patent changes the parameter of treatment selectivity by shifting from non-specific physical/chemical destruction (radiotherapy/chemotherapy) to targeted molecular inhibition. By monitoring chromosomal instability markers and cytosolic DNA levels, the treatment dynamically adjusts to target only cells with metastatic potential, transforming the selectivity parameter from low to high.
3Reliability
If immunotherapy using cytokines is used to treat cancer, then immune response is activated, but serious toxicity occurs
Solution Approach 1:
The patent introduces molecular intermediaries (cGAS inhibitors, STING inhibitors, NF-κB pathway modulators) that mediate the immune response without requiring high-dose cytokines. These intermediaries block the toxic inflammatory cascade while preserving anti-tumor immunity, acting as controlled mediators between the immune system and tumor cells.
4Duration of action of stationary object
If continuous use of cancer vaccines is used to maintain immune response, then cancer immunity is sustained, but immune tolerance develops
Solution Approach 1:
The patent implements periodic action by using intermittent treatment regimens that target chromosomal instability and cytosolic DNA at specific time points, rather than continuous vaccination. This periodic targeting of molecular markers prevents immune tolerance while maintaining sustained anti-tumor immunity through repeated but spaced interventions.
Data Source
AI summary
As described herein, chromosomal missegregations, chromosomal micromodel, cytosolic DNA, and combinations thereof are indicative of metastatic cancer. Methods and compositions are described herein that are useful for detection and treatment of patients with chromosomal instabilities such as chromosomal missegregations, chromosomal micromilei, cytosilic DNA, and combinations thereof. For example, some of the methods and compositions include use of kinesin-13 proteins such as Kif2b, MCAK/Kif2 or KIF13A. The methods and compositions can also include is of STING, ENPPI, cGAS, NF-kB transcription factor p52, NF-kB transcription factor ReIB, or any combination thereof. Methods are also described for identifying compounds that are effective for treatment of cancer, including metastic cancer.